StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Failure to meet trial endpoints negatively impacts market confidence, affecting ANAB’s valuation. Historically, stocks often drop significantly following disappointing clinical trial results.
What happened, with direct paths to the underlying reporting
Rosnilimab failed to meet primary efficacy endpoints in ulcerative colitis trial. Phase 2 trial discontinuation may save AnaptysBio over $10 million. Rosnilimab showed safety but low remission rates at Week 12. Future updates on rosnilimab for rheumatoid arthritis expected in H1 2026. Anaptys plans to separate biopharma assets from royalty revenues in 2026.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.